Drug Formulary Committee

Dec. 16, 2026
Public Meeting – 9 a.m. to 1:30 p.m. (Central Time)

ALL MEMBERS OF THE GENERAL PUBLIC CAN ACCESS THE MEETING AS FOLLOWS:

Virtual option:

Webinar Registration Link: Minnesota Drug Formulary Committee Meeting Webinar Registration

We recommend you register in advance to attend the webinar. After registering, you will receive a confirmation email containing information about joining the webinar.

The webinar will be open at 9 a.m. (Central Time) on Dec. 16, 2026.

Directions for the public to sign up to provide live testimonials via webinar during the public forum:

- Interested parties who wish to provide live testimonials during the public forum should email mn.dhs.dfc@state.mn.us no later than Dec. 16, 2026, 9 a.m. (Central Time) AND register for the webinar using the webinar registration link provided on this page before the date of the webinar.
- **Interested parties must include a completed Minnesota Drug Formulary Committee Meeting Public Comment Disclosure Form (PDF) in their email request.**
- Interested parties who sign up to provide live testimonials must check in to the webinar by 9:15 a.m. (Central Time) and be ready to provide their testimonials when their names are called. Their lines will be unmuted during the public forum. All other lines will be muted.
- An interested party's testimonial is limited to three minutes. If more than 20 people wish to provide public comment during the public forum, we will reduce the time to ensure all people are able to provide comment before the committee.

In-person option:

Elmer Andersen Building, Room 2370
540 Cedar Street
St. Paul, MN 55101

Note: All Drug Formulary Committee members will participate in the meeting virtually.

Directions for the public to sign up to provide live testimonials in person during the public forum:

- Interested parties who wish to provide live testimonials during the public forum should email mn.dhs.dfc@state.mn.us no later than Dec. 16, 2026, 9 a.m. (Central Time).
- **Interested parties must include a completed Minnesota Drug Formulary Committee Meeting Public Comment Disclosure Form (PDF) in their email request.**

- Interested parties who sign up to provide live testimonials in person must be present in room 2370 of Elmer Andersen Building at 9:15 a.m. (Central Time) and be ready to provide their testimonials when their names are called.
- An interested party's testimonial is limited to three minutes. If more than 20 people wish to provide public comment during the public forum, we will reduce the time to ensure all people are able to provide comment before the committee.

Email all questions regarding the Drug Formulary Committee meeting to: mn.dhs.dfc@state.mn.us.

Check-In (in-person and virtual): 9 to 9:15 a.m. (Central Time)

Public Meeting: 9:15 a.m. to 1:30 p.m. (Central Time)

Find the meeting materials in the "Meeting materials" section on the Drug Formulary Committee webpage

1. Public Forum 9:15 a.m. up to 10:15 a.m. (Central Time)
2. Report of the Chair
3. Approval of the Minutes
4. DHS Housekeeping
5. Old Business:
6. New Business

Specialty Drugs for Continued PA

Discussion Items:
1. Isturisa
2. Filsapri
3. Lynavoy
4. Trutakna
5. Besremi
6. Lumvoa

Preferred Drug List (PDL) Review

Discussion Items:

1. ANDROGENIC AGENTS
2. ANTIHISTAMINES, MINIMALLY SEDATING
3. ANTIPARASITICS, TOPICAL
4. ERYTHROPOIESIS STIMULATING PROTEINS
5. GLUCAGON AGENTS
6. HISTAMINE II RECEPTOR BLOCKER
7. IMMUNOMODULATORS, ATOPIC DERMATITIS
8. LIPOTROPICS, OTHER
9. MACROLIDES/KETOLIDES
10. NEUROPATHIC PAIN AND SELECT AGENTS

11. OPHTHALMICS, ANTI-INFLAMMATORIES
12. OPHTHALMICS, GLAUCOMA AGENTS AND RELATED AGENTS
13. PHOSPHATE BINDERS
14. SEDATIVE HYPNOTICS

Consent Agenda Items:

1. ANTIBIOTICS, INHALED
2. ANTIBIOTICS, TOPICAL
3. BLADDER RELAXANT PREPARATIONS
4. HEMOPHILIA TREATMENTS
5. HYPOGLYCEMICS, ALPHA-GLUCOSIDASE INHIBITORS
6. HYPOGLYCEMICS, TZD
7. INTRANASAL RHINITIS AGENTS
8. LEUKOTRIENE MODIFIERS
9. LIPOTROPICS, STATINS
10. OPHTHALMICS FOR ALLERGIC CONJUNCTIVITIS
11. OPHTHALMICS, DRY EYE AGENTS
12. PAH AGENTS, ORAL AND INHALED
13. PANCREATIC ENZYMES
14. PLATELET AGGREGATION INHIBITORS
15. PROGESTINS FOR CACHEXIA
16. PROTON PUMP INHIBITORS
17. SICKLE CELL ANEMIA TREATMENTS ULCERATIVE COLITIS AGENTS

Adjourn